Extrapyramidal side effects with low doses of amisulpride.
Nikhiles Mandal1, Om P Singh1, Subrata Sen1
1Department of Psychiatry, Burdwan Medical College and Hospital, Burdwan, West Bengal, India.
Indian Journal of Psychiatry
|June 4, 2014
Summary
Amisulpride, an antipsychotic, is thought to have low extrapyramidal side effects (EPS). However, this study reports EPS, including akathisia and Parkinsonism, even at low doses of amisulpride.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Amisulpride is a newer antipsychotic in India for schizophrenia.
- It is claimed to have minimal serotonergic activity and low incidence of extrapyramidal symptoms (EPS) due to limbic selectivity and lower striatal dopamine receptor binding.
- Clinical observations suggest otherwise, with EPS occurring even at low doses.
Purpose of the Study:
- To report cases of extrapyramidal symptoms (EPS) associated with low-dose amisulpride.
- To highlight the potential for EPS in clinical practice when using amisulpride.
- To emphasize the need for further research on amisulpride's EPS incidence and mechanisms in India.
Main Methods:
- Case report series.
- Clinical observation of patients treated with low-dose amisulpride.
Main Results:
- Three cases of EPS, including akathisia, acute dystonia, and drug-induced Parkinsonism, were observed.
- These side effects occurred at low doses of amisulpride, contradicting initial claims.
Conclusions:
- Extrapyramidal symptoms (EPS) can occur with amisulpride, even at lower therapeutic doses.
- Clinicians should be vigilant for EPS when prescribing amisulpride.
- Further studies are needed in India to determine the actual incidence and underlying mechanisms of amisulpride-induced EPS.
More Related Videos
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
06:25Paw-Print Analysis of Contrast-Enhanced Recordings PrAnCER: A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
Published on: August 12, 2019
10.7K
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
1.2K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.2K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.9K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
960
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
960
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K